AIM: To explore the association between serum α-Lfucosidase(Af U) and non-alcoholic fatty liver disease(NAf LD).METHODS: A total of 16473 individuals(9456 men and 7017 women) were included in the current study, who p...AIM: To explore the association between serum α-Lfucosidase(Af U) and non-alcoholic fatty liver disease(NAf LD).METHODS: A total of 16473 individuals(9456 men and 7017 women) were included in the current study, who presented for a health examination at the first Affiliated hospital of Zhejiang University School of medicine in 2014. The baseline characteristics of the cohort were compared by NAf LD status. Linear regression analysis and stepwise multiple regression analysis were applied to assess the risk factors for NAf LD. Receiver operating characteristic curve was used to determine the sensitivity and specificity of Af U in the diagnosis of NAf LD.RESULTS: The prevalence rates of NAf LD and metabolic syndrome(met S) were 38.0% and 25.4%, respectively. The NAf LD group had significantly higher Af U levels than the non-NAf LD group(28.7 ± 7.9 U/L vs 26.0 ± 7.3 U/L, P < 0.001) and the prevalence rate of NAf LD increased with progressively higher serum Af U levels. Af U was positively correlated with met S and its five components: central obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, and elevated blood pressure and fasting glucose. Stepwise multiple logistic regression analysis showed that Af U was associated with an increased risk of NAf LD(OR = 1.009, 95%CI: 1.003-1.014, P < 0.001). The best cut-off value of Af U for the diagnosis of NAf LD was 27.5 U/L. The area under the curve(diagnostic efficacy index) was 0.606. The sensitivity and specificity were 54.6% and 61.8%, respectively. CONCLUSION: Af U level is significantly associated with NAf LD, and elevated Af U level is an independent risk factor for NAf LD.展开更多
α-L-fucosidasc (AFU) activity was determined by referring to Troost’s method in sera, liv-er tissues and lesions from patients with hepatoccllular carcinoma (HCC), other liverspace-occupying lesions (SOL) and diseas...α-L-fucosidasc (AFU) activity was determined by referring to Troost’s method in sera, liv-er tissues and lesions from patients with hepatoccllular carcinoma (HCC), other liverspace-occupying lesions (SOL) and diseases. The results showed that the sensitivity and specificityfor the diagnosis of HCC were 81.2% and 83. 3% respectively with the assay of serum AFU activi-ty, and sensitivities in the diagnosis of AFP-negative and early HCC were 76.1% and 70. 8%,respectively. The AFU activity in the HCC tissues and their pericancerous liver tissues was twice asmuch as controls, and consisted with their serum AFU activity (r=0. 742, P【0.01). It is sug-gested that AFU could be a new biologic marker of HCC and have an important value in thediagnosis of HCC.展开更多
目的分析在诊断原发性肝癌患者时采取血清α-L-岩藻糖苷酶(α-l-fucosidase,AFU)、甲胎蛋白(α-fetoprotein,AFP)、异常凝血酶原Ⅱ(Protein Induced by Vitamin K Absence or Antagonist-Ⅱ,PIVKA-Ⅱ)检测的价值。方法选取2022年8月—2...目的分析在诊断原发性肝癌患者时采取血清α-L-岩藻糖苷酶(α-l-fucosidase,AFU)、甲胎蛋白(α-fetoprotein,AFP)、异常凝血酶原Ⅱ(Protein Induced by Vitamin K Absence or Antagonist-Ⅱ,PIVKA-Ⅱ)检测的价值。方法选取2022年8月—2023年8月邳州市中医院收治的83例原发性肝癌患者以及肝硬化患者作为研究对象,依据疾病类型不同,分为良性组(肝硬化患者41例)、观察组(原发性肝癌患者42例),另选择83例健康人群作为对照组。检测3组血清AFU、AFP、PIVKA-Ⅱ指标,分析上述指标水平,同时通过ROC曲线分析单项以及联合检测诊断原发性肝癌的价值。结果两组患者AFU、AFP、PIVKA-Ⅱ指标均显著高于对照组,且观察组AFU、AFP、PIVKA-Ⅱ指标水平高于良性组,差异有统计学意义(P均<0.05)。联合检测时,AUC提升至0.912,灵敏度提升至89.63%,特异度提升至99.10%,高于单独检测。结论在诊断原发性肝癌患者中,采用联合AFU、AFP、PIVKA-Ⅱ检测方式,有较为理想的诊断价值,能够为完善治疗方案奠定基础,可以作为诊断原发性肝癌的有效方法之一。展开更多
基金Supported by National Key Basic Research Development ProgramNo.2012CB524905+9 种基金National Science and Technology Support Plan ProjectNo.2012BAI06B04National Natural Science Foundation of ChinaNo.81100278No.81170378No.81230012 and No.81270487International Science and Technology Cooperation Projects of Zhejiang ProvinceNo.2013C24010Science Fund of Health Bureau of Zhejiang ProvinceNo.2012RCA026
文摘AIM: To explore the association between serum α-Lfucosidase(Af U) and non-alcoholic fatty liver disease(NAf LD).METHODS: A total of 16473 individuals(9456 men and 7017 women) were included in the current study, who presented for a health examination at the first Affiliated hospital of Zhejiang University School of medicine in 2014. The baseline characteristics of the cohort were compared by NAf LD status. Linear regression analysis and stepwise multiple regression analysis were applied to assess the risk factors for NAf LD. Receiver operating characteristic curve was used to determine the sensitivity and specificity of Af U in the diagnosis of NAf LD.RESULTS: The prevalence rates of NAf LD and metabolic syndrome(met S) were 38.0% and 25.4%, respectively. The NAf LD group had significantly higher Af U levels than the non-NAf LD group(28.7 ± 7.9 U/L vs 26.0 ± 7.3 U/L, P < 0.001) and the prevalence rate of NAf LD increased with progressively higher serum Af U levels. Af U was positively correlated with met S and its five components: central obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, and elevated blood pressure and fasting glucose. Stepwise multiple logistic regression analysis showed that Af U was associated with an increased risk of NAf LD(OR = 1.009, 95%CI: 1.003-1.014, P < 0.001). The best cut-off value of Af U for the diagnosis of NAf LD was 27.5 U/L. The area under the curve(diagnostic efficacy index) was 0.606. The sensitivity and specificity were 54.6% and 61.8%, respectively. CONCLUSION: Af U level is significantly associated with NAf LD, and elevated Af U level is an independent risk factor for NAf LD.
文摘α-L-fucosidasc (AFU) activity was determined by referring to Troost’s method in sera, liv-er tissues and lesions from patients with hepatoccllular carcinoma (HCC), other liverspace-occupying lesions (SOL) and diseases. The results showed that the sensitivity and specificityfor the diagnosis of HCC were 81.2% and 83. 3% respectively with the assay of serum AFU activi-ty, and sensitivities in the diagnosis of AFP-negative and early HCC were 76.1% and 70. 8%,respectively. The AFU activity in the HCC tissues and their pericancerous liver tissues was twice asmuch as controls, and consisted with their serum AFU activity (r=0. 742, P【0.01). It is sug-gested that AFU could be a new biologic marker of HCC and have an important value in thediagnosis of HCC.
文摘目的分析在诊断原发性肝癌患者时采取血清α-L-岩藻糖苷酶(α-l-fucosidase,AFU)、甲胎蛋白(α-fetoprotein,AFP)、异常凝血酶原Ⅱ(Protein Induced by Vitamin K Absence or Antagonist-Ⅱ,PIVKA-Ⅱ)检测的价值。方法选取2022年8月—2023年8月邳州市中医院收治的83例原发性肝癌患者以及肝硬化患者作为研究对象,依据疾病类型不同,分为良性组(肝硬化患者41例)、观察组(原发性肝癌患者42例),另选择83例健康人群作为对照组。检测3组血清AFU、AFP、PIVKA-Ⅱ指标,分析上述指标水平,同时通过ROC曲线分析单项以及联合检测诊断原发性肝癌的价值。结果两组患者AFU、AFP、PIVKA-Ⅱ指标均显著高于对照组,且观察组AFU、AFP、PIVKA-Ⅱ指标水平高于良性组,差异有统计学意义(P均<0.05)。联合检测时,AUC提升至0.912,灵敏度提升至89.63%,特异度提升至99.10%,高于单独检测。结论在诊断原发性肝癌患者中,采用联合AFU、AFP、PIVKA-Ⅱ检测方式,有较为理想的诊断价值,能够为完善治疗方案奠定基础,可以作为诊断原发性肝癌的有效方法之一。
